Saratin (an inhibitor of platelet-collagen interaction) decreases platelet aggregation and homocysteine-mediated postcarotid endarterectomy intimal hyperplasia in a dose-dependent manner

BACKGROUND: This study investigated Saratin's (Merck KGaA, Darmstadt, Germany) prevention of platelet adhesion and intimal hyperplasia at different doses and in the hyperhomocystinemia rat carotid endarterectomy (CEA) model. METHODS: Rats were divided into two groups: (1) platelet adhesion or (2) luminal stenosis because of intimal hyperplasia. At CEA, rats received 0, 0.5, 5.0, 10.0, or 20.0 microg Saratin on the artery. Post-CEA platelet aggregation was evaluated by standard error of the mean. Intimal hyperplasia group received either (1) control or (2) 4.5 g/kg DL-homocystine diets for two weeks followed by CEA and treated with diluent or 5.0 microg Saratin. Endpoints included platelet adhesion, intimal hyperplasia, plasma homocysteine (HCys), and its metabolic enzymes cystathionine beta-synthase (CBS) and methylenetetrahydrofolate reductase (MTHFR). RESULTS: Platelet adhesion: post-CEA, platelet adhesion was reduced by 63%, 67%, and 67% in Saratin doses > or =5.0 microg. Intimal hyperplasia: 5.0 microg Saratin in the HCys group decreased intimal hyperplasia by 45% compared with the non-Saratin-treated HCys group. Plasma HCys levels were not altered with Saratin treatment in the HCys groups nor were CBS or MTHFR. CONCLUSIONS: Saratin significantly inhibited platelet adhesion at > or =5.0 microg, and Saratin at 5.0 microg attenuated luminal stenosis in a hyperhomocysteinemic rat CEA model.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

In a rat carotid endarterectomy model, Saratin doses of 5.0 microg or more applied to the artery reduced platelet adhesion by 63-67%, and 5.0 microg reduced intimal hyperplasia by 45% in hyperhomocysteinemic animals without altering homocysteine levels.

Explore how this research connects to clinical practice

More peer-reviewed studies in Salivary Pharmacology.

• Medicinal leeches and hirudotherapy — Gödekmerdan A et al. (2011)
• PEROXIDATION OF SALIVA LIPIDS IN PATIENTS WITH POSTCOVID SYNDROME DURING HIRUDOTHERAPY — Serikbayeva S et al. (2024)
• Medicinal leech therapy in pain syndromes: a narrative review — Koeppen D, Aurich M, Rampp T (2014)
• Immunomodulatory effects of medicinal leech saliva extract on in vitro activated macrophages — Ayhan H et al. (2024)
• Proteinase inhibitors from the medicinal leech Hirudo medicinalis — Baskova I, Zavalova L (2001)
• Polyfunctionality of destabilase, a lysozyme from a medicinal leech — Baskova I, Zavalova L (2008)
• Make it double: identification and characterization of a Tandem-Hirudin from the Asian medicinal leech Hirudinaria manillensis — Lukas P et al. (2022)
• Use of the medicinal leech in the treatment of ear diseases — Seleznev K et al. (1992)
• Recombinant Destabilase from Hirudo medicinalis Is Able to Dissolve Human Blood Clots In Vitro — Bobrovsky P et al. (2021)
• Effects of Carbon Nanotube Environmental Dispersion on an Aquatic Invertebrate, Hirudo medicinalis — Girardello R et al. (2015)

Browse all ASH-analysed research →